Find a Clinical Trial
Filter
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
Bladder cancer
All genders
18+
Recruiting now
Department of Medicine, Cancer Center
A clinical trial investigating BNT113 in combination with pembrolizumab versus pembrolizumab alone for patients with a form of head and neck cancer positive for human papilloma virus 16 and expressing the protein PD-L1
Head and neck cancer
All genders
18+
Recruiting now
Cancer Center
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Squamous cell carcinoma
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
EA3191
Head and neck cancer
All genders
18-79
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Multi-spectral imaging
Ovarian cancer
Female
18-99
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)
Endometrial cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center